The Preclinical Testing Consortium (PPTC) is a US National Cancer Institute-funded initiative aimed at prioritizing effective drugs for clinical evaluation in pediatric cancers. OT-82 was selected for testing into this program. Results obtained with OT-82 showed impressive effectiveness in systemic patient-derived xenografts from pediatric resistant ALL patients. In addition, OT-82 demonstrated synergy with AraC in combination therapy. Consequently NAMPT inhibition by OT-82 is an attractive strategy for treating leukemia, and these data support further evaluation of this drug in the treatment of high-risk pediatric ALL.